2796 — Pharmarise Holdings Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesConservativeMicro CapValue Trap

Annual income statement for Pharmarise Holdings, fiscal year end - May 31st, JPY millions except per share, conversion factor applied.

	2021 May 31st	2022 May 31st	2023 May 31st	2024 May 31st	2025 May 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Yuho
Standards:	JAS	JAS	JAS	JAS	JAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	52,324	51,608	52,030	54,466	63,508
Cost of Revenue
Gross Profit	8,068	8,117	8,134	8,449	8,966
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	51,446	50,306	50,969	54,257	63,388
Operating Profit	878	1,302	1,061	209	120
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	1,202	1,322	1,049	143	-35
Provision for Income Taxes
Net Income After Taxes	420	458	347	-342	-425
Minority Interest
Net Income Before Extraordinary Items
Net Income	426	448	333	-351	-412
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	428	449	335	-351	-410
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	110	104	97.6	63.3	40
Dividends per Share
Special Dividends per Share